Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × INDUSTRY × AML × Clear all

Phase

Phase 1/2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 1382 Carcinoma, Non-Small-Cell Lung 670 Breast Neoplasms 514 Neoplasm Metastasis 473 Colorectal Neoplasms 386 Melanoma 350 Leukemia, Myeloid, Acute 338 Multiple Myeloma 327 Ovarian Neoplasms 315 Recurrence 307 Lymphoma 307 Advanced Solid Tumors 291 Lymphoma, Non-Hodgkin 278 Prostatic Neoplasms 262 Pancreatic Neoplasms 251 Advanced Solid Tumor 216 Carcinoma, Renal Cell 205 Stomach Neoplasms 203 Solid Tumor 187 Squamous Cell Carcinoma of Head and Neck 185 Lung Neoplasms 185 Leukemia, Lymphocytic, Chronic, B-Cell 175 Triple Negative Breast Neoplasms 161 Solid Tumors 160 Carcinoma, Hepatocellular 144 Hematologic Neoplasms 140 Lymphoma, Large B-Cell, Diffuse 133 Head and Neck Neoplasms 133 Lymphoma, Follicular 131 Glioblastoma 128

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06731699 2024-12-17

A Phase 1 Study of FD-001 in Recurrent /Refractory (R/R)AML/NHL/MM/MDS

Chengdu FenDi Pharmaceutical Co., Ltd.

Phase 1 Recruiting

AML

Data powered by HemOnc (CC BY 4.0) Colophon ⚡